Compounds / Cognitive / PE-22-28

PE-22-28

PE-22-28 (TREK-1 Potassium Channel Antagonist — Antidepressant Peptide)
CognitiveEmerging ResearchFDA: Not approved; preclinical research

Overview

Preclinical: rapid antidepressant-like effects, enhanced neurogenesis, neuroprotection. Favorable safety profile. High potency — 100–150 mcg often sufficient. No human trials yet.

Mechanism of Action

Synthetic heptapeptide (GVSWGLR) derived from sortilin propeptide. Potent selective TREK-1 potassium channel antagonist. TREK-1 blockade → antidepressant-like effects. Rapid neurogenesis. No cardiac or metabolic side effects in preclinical studies.

Molecular Profile

Molecular weight
773.89 Da
Type
Linear heptapeptide
Length
7 amino acids
Gly-Val-Ser-Trp-Gly-Leu-Arg (GVSWGLR)

Key Research Findings

TREK-1 antagonism; rapid antidepressant effects; neurogenesis; no cardiac side effects; preclinical only.

Published Research

Neuropharmacology (2019)
Djillani A et al. Identification and characterization of PE-22-28, a potent and selective blocker of TREK-1
View source

Related Cognitive Compounds

SemaxNA Semax AmidateSelankAdalankAdamaxDihexa
Clinical Guidance

Research data is not a treatment plan. If you are considering PE-22-28, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running PE-22-28? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals